MPNs | Clinical

Treatment with Momelotinib Shows Significant Improvement in Myelofibrosis Conditions

January 31, 2023

Findings from the MOMENTUM phase 3 study show that the use of momelotinib significantly impacts patients with myelofibrosis.

Challenges of Treating Patients With Cytopenias in Myelofibrosis

January 17, 2023

Srdan Verstovsek, MD, PhD, discusses the issues faced by patients with cytopenic myelofibrosis.

Navitoclax Added to Ruxolitinib Improves Spleen Volume and Symptoms in Myelofibrosis

January 17, 2023

The ability to modify disease in patients with myelofibrosis was signaled in the REFINE study. The combination also displayed positive efficacy and was tolerable.

Roundtable Discussion: Komrokji Evaluates Pathology, Risk Assessment, and Therapy for Myelofibrosis

January 14, 2023

During a Targeted Oncology case-based roundtable event, Rami Komrokji, MD, discussed with participants their approach toward assessing and treating a patient with symptoms possibly indicating primary myelofibrosis.

Momelotinib Continues to Prove Itself as a Potential Treatment for Myelofibrosis

January 11, 2023

In an interview with Targeted Oncology, Srdan Verstovsek, MD, discussed the potential use of momelotinib as a treatment for patients with myelofibrosis if approved by the FDA in June 2023.

Ruxolitinib’s Role for Symptoms and Survival Benefit in Myelofibrosis

January 04, 2023

During a Targeted Oncology case-based roundtable event, Rami Komrokji, MD, discussed data supporting the use of ruxolitinib and what role it may play in improving long-term outcomes for patients with myelofibrosis. This is the second of 2 articles based on this event.

Initiating Therapy for Myelofibrosis Based on Risk Assessment

December 27, 2022

During a Targeted Oncology case-based roundtable event, Rami Komrokji, MD, and participants discussed when to start treatment for patients with myelofibrosis.

Low Platelet Counts Linked With Greater Symptom Burden in Myelofibrosis

December 16, 2022

A more severe symptom burden was seen in patients with isolated thrombocytopenia vs those with isolated anemia, according to findings from the phase 3 PERSIST-1 and PAC203 trials in myelofibrosis.

Momelotinib Responses Last for Up to 11 Months Patients With Anemic Myelofibrosis

December 12, 2022

The MOMENTUM trial continues to show positive results for momelotinib fro the treatment of anemic myelofibrosis.

When to Stop or Switch JAK Inhibitor Therapy in Myelofibrosis

December 12, 2022